Factors affecting treatment selection and overall survival for first-line EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer
Aim: To investigate the factors associated with treatment selection and overall survival for
first-line EGFR-tyrosine kinase inhibitors (EGFR-TKIs) therapy among patients with non …
first-line EGFR-tyrosine kinase inhibitors (EGFR-TKIs) therapy among patients with non …
Molecular docking, QSAR, and simulation analyses of EGFR-targeting phytochemicals in non-small cell lung cancer
Non-small cell lung carcinoma (NSCLC) is one of the prominent categories of cancer
worldwide. It is primarily linked to mutations in the EGFR kinase domain, leading to being …
worldwide. It is primarily linked to mutations in the EGFR kinase domain, leading to being …
Tissue or liquid rebiopsy? A prospective study for simultaneous tissue and liquid NGS after first‐line EGFR inhibitor resistance in lung cancer
YT Lin, CC Ho, WH Hsu, WY Liao, CY Yang… - Cancer …, 2024 - Wiley Online Library
Abstract Introduction According to current International Association for the Study of Lung
Cancer guideline, physicians may first use plasma cell‐free DNA (cfDNA) methods to …
Cancer guideline, physicians may first use plasma cell‐free DNA (cfDNA) methods to …
Sequential treatment in advanced epidermal growth factor receptor-mutated lung adenocarcinoma patients receiving first-line bevacizumab combined with 1st/2nd …
PC Hsu, CY Huang, YC Lin, SH Lee, LC Chiu… - Frontiers in …, 2023 - frontiersin.org
Introduction The clinical outcomes of sequential treatment of advanced epidermal growth
factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) patients with first-line …
factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) patients with first-line …
Biomarkers involved in the proliferation of the odontogenic keratocyst, glandular odontogenic cyst and botryoid odontogenic cyst
JF Júnior, GM de França, CC da Silva Barros… - Oral and Maxillofacial …, 2022 - Springer
Introduction Odontogenic cysts are a heterogeneous group of lesions with varied clinical
behavior. Objective To analyze the expression of the epidermal growth factor receptor …
behavior. Objective To analyze the expression of the epidermal growth factor receptor …
First‐line treatment with irreversible tyrosine kinase inhibitors associated with longer OS in EGFR mutation‐positive non‐small cell lung cancer
Background Few studies have compared the efficacy of the irreversible epidermal growth
factor receptor tyrosine kinase inhibitor (EGFR‐TKI), afatinib, with that of reversible EGFR …
factor receptor tyrosine kinase inhibitor (EGFR‐TKI), afatinib, with that of reversible EGFR …
Differential prognostic value of tumor and plasma T790M mutations in EGFR TKI-treated advanced NSCLC
PH Tung, TH Chiu, ACC Huang, JS Ju… - Therapeutic …, 2024 - journals.sagepub.com
Background: Substitution of methionine for threonine at codon 790 (T790M) of epidermal
growth factor receptor (EGFR) represents the major mechanism of resistance to EGFR …
growth factor receptor (EGFR) represents the major mechanism of resistance to EGFR …
[HTML][HTML] Review of epidermal growth factor receptor-tyrosine kinase inhibitors administration to non-small-cell lung cancer patients undergoing hemodialysis
CC Lan, PC Hsieh, CY Huang, MC Yang… - World Journal of …, 2022 - ncbi.nlm.nih.gov
Non-small-cell lung cancer (NSCLC) causes significant mortality worldwide. Patients with
chronic renal failure have an increased risk of developing lung cancer. NSCLC Patients with …
chronic renal failure have an increased risk of developing lung cancer. NSCLC Patients with …
Integration of genomic profiling and organoid development in precision oncology
H Yoon, S Lee - International Journal of Molecular Sciences, 2021 - mdpi.com
Precision oncology involves an innovative personalized treatment strategy for each cancer
patient that provides strategies and options for cancer treatment. Currently, personalized …
patient that provides strategies and options for cancer treatment. Currently, personalized …
A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in …
HY Tu, J Feng, M Shi, J Zhao, Y Wang, J Chang… - Targeted Oncology, 2022 - Springer
Background Afatinib has been shown as a suitable option for the treatment of epidermal
growth factor receptor mutation-positive (EGFR m+) non-small-cell lung cancer (NSCLC) in …
growth factor receptor mutation-positive (EGFR m+) non-small-cell lung cancer (NSCLC) in …